Please login to the form below

Not currently logged in
Email:
Password:

ataluren

This page shows the latest ataluren news and features for those working in and with pharma, biotech and healthcare.

Duchenne UK backs Evox dystrophin delivery project

Duchenne UK backs Evox dystrophin delivery project

At the moment that includes already-market drugs that skip over or ignore the mutation in the dystrophin gene – such as PTC Therapeutics’ Translarna (ataluren) and Sarepta’s Exondys 51 (eteplirsen) –

Latest news

More from news
Approximately 3 fully matching, plus 19 partially matching documents found.

Latest Intelligence

  • Pharma deals during January 2014 Pharma deals during January 2014

    In 2008 Genzyme gained rights to ataluren from PTC Therapeutics at a cost of $100m. ... Ataluren was in clinical development for the treatment of Duchenne muscular dystrophy caused by nonsense mutations.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...

Infographics